A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) forRN0361-an ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Given the growing antibiotic resistance crisis, novel ways to target bacterial infections are becoming increasingly important. One potential strategy is to manipulate bacterial genes at the ...

Generation Bio Co. is developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle technology. This innovative delivery system aims to ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases- Lead target ...

“This financing validates the truly transformative potential of Atalanta’s best-in-class di-siRNA platform for delivering oligonucleotide therapies to the central nervous system and the ...